RNAlater® Tissue Collection: RNA Stabilization Solution is an aqueous, non-toxic tissue storage reagent that protects RNA within intact, unfrozen tissue and cell samples. RNAlater® was designed to eliminate the need to immediately process tissue samples or, alternatively, to freeze samples in liquid nitrogen for later processing. Tissue handling during sample collection is an important aspect of preserving clinical samples for both histological and molecular analyses. Dr. Dondapati Chowdary and colleagues (Veridex LLC, Warren, NJ) designed a study to assess gene expression profiling from paired tumor samples (RNAlater-preserved compared to snap-frozen tissue from the same patient) on Affymetrix® GeneChip® arrays . They demonstrated concordance between gene expression profiles and a correlation with predictions of cancer relapse from the paired samples.
Gene Expression Profiling Using Clinical Samples
Sample preservation (i.e., stabilization of nucleic acids) has always been an important aspect of gene expression studies, but adapting sample collection protocols to a clinical setting can be difficult when the priority is the surgery and/or the pathologist’s assessment. Since liquid nitrogen is usually not available in most operating rooms, tissues obtained from surgery are often stored at ambient temperature or on ice for varying periods of time. While these samples may still have diagnostic and prognostic value for the pathologist, the RNA degradation that occurs during this period can result in assay variability and compromised reproducibility. The RNA modification and cleavage that occurs with formalin fixation: paraffin embedding (FFPE) protocols also complicates global gene expression profiling experiments.
RNAlater® Solution Preserves Expression Profiles
Gene Expression Profiles: Based on analysis using an Agilent® bioanalyzer, no significant differences in RNA yield and quality were observed between RNA isolated from RNA later-treated or snap-frozen samples. Biotin labeled cRNA targets were amplified utilizing RNA from matched colon and breast tumor sample pairs and hybridized to Affymetrix U133A arrays. Strong correlations in global expression levels were observed in each matched sample pair (median Pearson correlation coefficients of 0.94 and 0.97 for colon tumor pairs and breast tumor pairs, respectively). Additional analyses were reported that examined false discovery rates, variability introduced by the sample acquisition protocol, overlap in differentially expressed genes between sample pairs, and hierarchical clustering to show relationships among gene expression patterns from each sample.
Prognostic Signatures: Using previously described algorithms [2, 3], a strong correlation in the Relapse Hazard Score (RHS) and prediction of cancer recurrence (96%) from the paired samples was observed. Not enough time has passed since sample collection to compare these results to actual relapse rates in these patient groups.
- Chowdary D, Lathrop J, Skelton J, Curtin K, Briggs T, Zhang Y, Yu J, Wang Y, Mazumder A (2006) Prognostic Gene Expression Signatures Can Be Measured in Tissues Collected in RNAlater Preservative. J Mol Diagn 8(1):31–9.
- Wang Y, Jatkoe T, Zhang Y, Mutch MG, Talantov D, Jiang J, McLeod HL, Atkins D.(2004) Gene expression profiles and molecular markers to predict recurrence of Dukes’ B colon cancer. J Clin Oncol 22(9):1564–71.
- Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460):671–9.